Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?
By the Top Tier Newswire AI Desk · November 17, 2026 at 2:10 PM ET · reviewed against 4 wire stories
TWIST BIOSCIENCE COR (TWST) is up +5.50% in the latest session. Our newswire has captured 4 stories on TWST across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 46/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Twist Bioscience (TWST) shares rose 5.50% to $110.81, driven by renewed analyst interest in its artificial intelligence drug discovery capabilities. The move followed a series of recent rating updates, including a price target reduction from Barclays, which maintained its stance on the stock.
What Happened
Barclays lowered its price target on Twist Bioscience to $130 from $215 while maintaining its rating. This action occurred alongside other recent adjustments from Wall Street, including Canaccord Genuity cutting its target to $150 and Baird raising its target to $135 while keeping a Buy rating. A 10-K filing highlighted financial challenges amidst growth opportunities, noting that the company remains unprofitable with a trailing twelve-month EPS of $2.08. However, analysts suggest that AI-driven drug discovery could justify the company's premium valuation, while cancer testing and repeat DNA orders may expand research and development demand.
What The Data Shows
The stock opened at $106.65, a 1.5% gap up from the prior close of $105.04. It hit a session low of $102.82 at 10:45 AM ET before climbing to a session high of $111.01 at 2:10 PM ET. Volume stood at 0.6 million shares, which is 0.3 times the three-month daily average. The company has a market capitalization of $7.0 billion and a beta of 2.22. Over the last 8 sessions, the stock declined 12.9% from $120.61 to $105.04. The 52-week range is $23.30 to $219.71. Recent insider activity includes 33 sells totaling $99.9 million in the last 90 days, with no buys recorded. Notable recent sales were filed by CEO Emily M. Leproust and President Patrick John Finn on November 3, 2026, and SVP of HR Paula Green on November 12, 2026.
What To Watch
Investors will monitor the breadth of analyst coverage following the recent price target adjustments. The stock's ability to sustain momentum above the $110 level will be key as it navigates its high beta and recent volatility.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech
The bull case for Twist Bioscience: AI drug discovery could justify its premium valuation, while cancer testing and repeat DNA orders may expand R&D demand.
4d agoGuruFocusBEARISH 42Analyst
TWST Maintained by Barclays -- Price Target Lowered to $130
4d agoThe FlyBEARISH 34Analyst
Twist Bioscience price target lowered to $130 from $215 at Barclays
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →